Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Biomea Fusion, Inc.BMEA · Entity 6606 | Director | June 10, 2026 | June 12, 2026 |
| Calithera Biosciences, Inc.CALA · Entity 113073 | See Remarks | January 25, 2022 | January 27, 2022 |
| Cue Biopharma, Inc.CUE · Entity 6301 | Chief Legal Compliance Officer · Corporate Secretary | October 12, 2026 | October 15, 2026 |
| Instil Bio, Inc.TIL · Entity 7177 | Chief Legal and Admin Officer | January 08, 2023 | January 20, 2023 |
| Vaxxinity, Inc.VAXX · Entity 91688 | Chief Legal, Comp & Admin Off | November 01, 2023 | April 29, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Biomea Fusion, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2036-06-09 | Direct | 196,299 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 196,299 · Balance 196,299 F1: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.
Calithera Biosciences, Inc.
Report date January 25, 2022 · Filed January 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.44 · Expires 2032-01-24 | Direct | 165,000 |
Reported balance
After 2022-01-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-25 · Grant · Acquired 165,000 · Balance 165,000 F1: One-fourth (1/4th) of the Option vests one year after January 25, 2022; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: One-fourth (1/4th) of the Option vests one year after January 25, 2022; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
Cue Biopharma, Inc.
Report date October 12, 2026 · Filed October 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 116,701 |
Reported balance
After 2026-10-12 transaction · row 1
1 source rowRow 1 · 2026-10-12 · Sale · Disposed 1,844 · Balance 116,701 F1: The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to satisfy mandatory tax withholding obligations through a "sell-to-cover" transaction in connection with the vesting and settlement of restricted stock units, and the Reporting Person did not exercise any control over the timing, price or number of shares sold. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to satisfy mandatory tax withholding obligations through a "sell-to-cover" transaction in connection with the vesting and settlement of restricted stock units, and the Reporting Person did not exercise any control over the timing, price or number of shares sold.
Instil Bio, Inc.
Report date January 08, 2023 · Filed January 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.63 · Expires 2033-01-07 | Direct | 415,000 |
Reported balance
After 2023-01-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-08 · Grant · Acquired 415,000 · Balance 415,000 F1: Twenty-five percent (25%) of the shares subject to the option vest on January 8, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2033-01-17 | Direct | 50,000 |
Reported balance
After 2023-01-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-18 · Grant · Acquired 50,000 · Balance 50,000 F2: Twenty-five percent (25%) of the shares subject to the option vest on January 18, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent (25%) of the shares subject to the option vest on January 8, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
F2: Twenty-five percent (25%) of the shares subject to the option vest on January 18, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
Vaxxinity, Inc.
Report date November 01, 2023 · Filed April 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.17 · Expires 2033-11-01 | Direct | 425,000 |
Reported balance
After 2023-11-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-11-01 · Grant · Acquired 425,000 · Balance 425,000 F1: These options are subject to a four-year vesting schedule, with 25% vesting one year after the vesting commencement date of October 1, 2023 and the remainder vesting in equal quarterly installments, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: These options are subject to a four-year vesting schedule, with 25% vesting one year after the vesting commencement date of October 1, 2023 and the remainder vesting in equal quarterly installments, subject to the Reporting Person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2026 Filed Oct 15, 2026 01:39 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 1,844 | $28.05 | $51,724.20 |
DisclosureSEC source: 0001579629-26-000012 · form4-10152026_011030.xml · nonDerivative · entry 1 Ray Sumita · CIK 0001579629 · Chief Legal Compliance Officer · Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,701 F1 · kind: The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to satisfy mandatory tax withholding obligations through a "sell-to-cover" transaction in connection with the vesting and settlement of restricted stock units, and the Reporting Person did not exercise any control over the timing, price or number of shares sold. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 22:22 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock · Derivative | 18,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001579629-26-000008 · form4-08172026_100832.xml · derivative · entry 5 Ray Sumita · CIK 0001579629 · Chief Legal Compliance Officer · Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,393 Underlying: Common Stock · 18,196 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The performance stock units ("PSU") were awarded subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. The award settled with respect to 1/3 of the PSUs underlying the award on August 13, 2026. The remaining 2/3 of the PSUs underlying the award are expected to settle on the achievement of a closing price per share of $38.50 and $44.00, in each case for a period of five consecutive trading days. F4 · derivative.exercise_date: The performance stock units ("PSU") were awarded subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. The award settled with respect to 1/3 of the PSUs underlying the award on August 13, 2026. The remaining 2/3 of the PSUs underlying the award are expected to settle on the achievement of a closing price per share of $38.50 and $44.00, in each case for a period of five consecutive trading days. F4 · derivative.expiration_date: The performance stock units ("PSU") were awarded subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. The award settled with respect to 1/3 of the PSUs underlying the award on August 13, 2026. The remaining 2/3 of the PSUs underlying the award are expected to settle on the achievement of a closing price per share of $38.50 and $44.00, in each case for a period of five consecutive trading days. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 22:22 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 4 | $31.13 | $124.52 |
DisclosureSEC source: 0001579629-26-000008 · form4-08172026_100832.xml · nonDerivative · entry 4 Ray Sumita · CIK 0001579629 · Chief Legal Compliance Officer · Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,545 F1 · kind: The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the reporting person. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 22:22 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 6,442 | $30.35 | $195,514.70 |
DisclosureSEC source: 0001579629-26-000008 · form4-08172026_100832.xml · nonDerivative · entry 3 Ray Sumita · CIK 0001579629 · Chief Legal Compliance Officer · Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,549 F1 · kind: The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the reporting person. F3 · price: The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $29.99 to $30.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 22:22 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 2,383 | $29.37 | $69,988.71 |
DisclosureSEC source: 0001579629-26-000008 · form4-08172026_100832.xml · nonDerivative · entry 2 Ray Sumita · CIK 0001579629 · Chief Legal Compliance Officer · Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,991 F1 · kind: The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the reporting person. F2 · price: The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $28.97 to $29.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 22:22 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 18,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001579629-26-000008 · form4-08172026_100832.xml · nonDerivative · entry 1 Ray Sumita · CIK 0001579629 · Chief Legal Compliance Officer · Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2026 Filed Jul 10, 2026 23:33 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantCommon Stock · Derivative | 54,589 | $0.00 | $0.00 |
DisclosureSEC source: 0001579629-26-000004 · form4-07102026_110713.xml · derivative · entry 2 Ray Sumita · CIK 0001579629 · Chief Legal Compliance Officer · Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,589 Underlying: Common Stock · 54,589 shares Expires not disclosed F2 · derivative.exercise_price: Represents the grant of performance stock units ("PSUs"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. F2 · derivative.exercise_date: Represents the grant of performance stock units ("PSUs"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. F2 · derivative.expiration_date: Represents the grant of performance stock units ("PSUs"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. Read SEC document |
| July 09, 2026 Filed Jul 10, 2026 23:33 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantCommon Stock | 54,589 | $0.00 | $0.00 |
DisclosureSEC source: 0001579629-26-000004 · form4-07102026_110713.xml · nonDerivative · entry 1 Ray Sumita · CIK 0001579629 · Chief Legal Compliance Officer · Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,178 F1 · shares: Represents that grant of restricted stock units ("RSUs"). The shares subject to the RSUs vest in equal quarterly installments over a period of forty-eight (48) months, measured from the date of grant, subject to the reporting person's continued service with the issuer through each vest date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:15 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantStock Option (Right to Buy) · Derivative | 196,299 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001193125-26-269468 · ownership.xml · derivative · entry 1 Ray Sumita · CIK 0001579629 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,299 Underlying: Common Stock · 196,299 shares Expires 2036-06-09 F1 · derivative.exercise_date: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:15 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantStock Option (Right to Buy) · Derivative | 91,970 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0000950170-25-086190 · ownership.xml · derivative · entry 1 Ray Sumita · CIK 0001579629 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,970 Underlying: Common Stock · 91,970 shares Expires 2035-06-10 F1 · derivative.exercise_date: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 20:30 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantStock Option (Right to Buy) · Derivative | 51,025 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0000950170-24-073075 · ownership.xml · derivative · entry 1 Ray Sumita · CIK 0001579629 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,025 Underlying: Common Stock · 51,025 shares Expires 2034-06-11 F1 · derivative.exercise_date: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| November 01, 2023 Filed Apr 29, 2024 16:15 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | GrantEmployee Stock option (right to buy) · Derivative | 425,000 | $0.00 Strike: $1.17 | $0.00 |
DisclosureSEC source: 0001415889-24-011661 · form4-04292024_040401.xml · derivative · entry 1 Ray Sumita · CIK 0001579629 · Chief Legal, Comp & Admin Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 425,000 Underlying: Class A Common Stock · 425,000 shares Expires 2033-11-01 F1 · derivative.exercise_date: These options are subject to a four-year vesting schedule, with 25% vesting one year after the vesting commencement date of October 1, 2023 and the remainder vesting in equal quarterly installments, subject to the Reporting Person's continued service. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:00 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantStock Option (Right to Buy) · Derivative | 6,989 | $0.00 Strike: $38.90 | $0.00 |
DisclosureSEC source: 0000950170-23-028670 · ownership.xml · derivative · entry 1 Ray Sumita · CIK 0001579629 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,989 Underlying: Common Stock · 6,989 shares Expires 2033-06-13 F1 · derivative.exercise_date: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| January 18, 2023 Filed Jan 20, 2023 21:06 UTC | Instil Bio, Inc. TIL · Entity 7177 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001789769-23-000006 · wf-form4_167424877162085.xml · derivative · entry 2 Ray Sumita · CIK 0001579629 · Chief Legal and Admin Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-01-17 F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on January 18, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 08, 2023 Filed Jan 20, 2023 21:06 UTC | Instil Bio, Inc. TIL · Entity 7177 | GrantEmployee Stock Option (right to buy) · Derivative | 415,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001789769-23-000006 · wf-form4_167424877162085.xml · derivative · entry 1 Ray Sumita · CIK 0001579629 · Chief Legal and Admin Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,000 Underlying: Common Stock · 415,000 shares Expires 2033-01-07 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on January 8, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 21:15 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantStock Option (Right to Buy) · Derivative | 23,867 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0000899243-22-024058 · doc4.xml · derivative · entry 1 Ray Sumita · CIK 0001579629 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,867 Underlying: Common Stock · 23,867 shares Expires 2032-06-21 F1 · derivative.exercise_date: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| March 03, 2022 Filed Mar 8, 2022 00:00 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantStock Option (Right to Buy) · Derivative | 21,461 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0000899243-22-009752 · doc4.xml · derivative · entry 1 Ray Sumita · CIK 0001579629 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,461 Underlying: Common Stock · 21,461 shares Expires 2032-03-02 F1 · derivative.exercise_date: The shares underlying the stock option shall vest in equal monthly installments over a three year period beginning on June 16, 2021, so that all shares shall have vested on June 16, 2024, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 16:17 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantEmployee Stock Option (Right to Buy) · Derivative | 165,000 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0000899243-22-003439 · doc4.xml · derivative · entry 1 Ray Sumita · CIK 0001579629 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2032-01-24 F1 · derivative.exercise_date: One-fourth (1/4th) of the Option vests one year after January 25, 2022; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 19:33 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-043686 · doc4.xml · nonDerivative · entry 1 Ray Sumita · CIK 0001579629 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 F1 · shares: The shares of Common Stock were acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. Read SEC document |
| October 27, 2021 Filed Oct 29, 2021 18:48 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantCommon Stock | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042063 · doc4.xml · nonDerivative · entry 1 Ray Sumita · CIK 0001579629 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,000 F1 · shares: The shares of Common Stock were acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 21:14 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantStock Option (Right to Buy) · Derivative | 17,724 | $0.00 Strike: $20.46 | $0.00 |
DisclosureSEC source: 0001567619-21-012451 · doc1.xml · derivative · entry 1 Ray Sumita · CIK 0001579629 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,724 Underlying: Common Stock · 17,724 shares Expires 2031-06-16 F1 · derivative.exercise_date: The shares underlying the stock option shall vest in equal monthly installments over a three year period beginning on June 16, 2021, so that all shares shall have vested on June 16, 2024, subject to the Reporting Person continued service to the Issuer through each vesting date. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 20:36 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantEmployee Stock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0000899243-21-003049 · doc4.xml · derivative · entry 3 Ray Sumita · CIK 0001579629 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-01-20 F4 · derivative.exercise_date: One-fourth (1/4th) of the Option vests one year after January 20, 2021; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 20:36 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-003049 · doc4.xml · nonDerivative · entry 2 Ray Sumita · CIK 0001579629 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 F3 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on January 3, 2022. The Restricted Stock Unit shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 20:36 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-003049 · doc4.xml · nonDerivative · entry 1 Ray Sumita · CIK 0001579629 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest as follows: one-fourth (1/4th) of the shares subject to the Restricted Stock Unit will vest each year after January 20, 2021 until the Restricted Stock Units are fully vested. The Restricted Stock Unit shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. F2 · balance_after: Includes 2,500 shares acquired under the Company's 2014 Employee Stock Purchase Plan on each of June 8, 2018, December 10, 2018, June 10, 2019, December 10, 2019, June 10, 2020 and December 10, 2020. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 18:12 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0000899243-20-001693 · doc4.xml · derivative · entry 1 Ray Sumita · CIK 0001579629 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2030-01-17 F1 · derivative.exercise_date: One-fourth (1/4th) of the Option vests one year after January 17, 2020; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the Company's Severance Benefit Plan. Read SEC document |
| January 10, 2019 Filed Jan 14, 2019 16:29 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0000899243-19-001124 · doc4.xml · derivative · entry 1 Ray Sumita · CIK 0001579629 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-01-09 F1 · derivative.exercise_date: One-fourth (1/4th) of the Option vests one year after January 10, 2019; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the Company's Severance Benefit Plan. Read SEC document |
| October 09, 2018 Filed Oct 11, 2018 17:44 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.61 | $0.00 |
DisclosureSEC source: 0000899243-18-026572 · doc4.xml · derivative · entry 1 Ray Sumita · CIK 0001579629 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-10-08 F1 · derivative.exercise_date: One-fourth (1/4th) of the Option vests one year after October 9, 2018; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the Company's Severance Benefit Plan. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 17:02 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $15.75 | $0.00 |
DisclosureSEC source: 0000899243-17-023313 · doc4.xml · derivative · entry 1 Ray Sumita · CIK 0001579629 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-09-29 F1 · derivative.exercise_date: One-fourth (1/4th) of the Option vests one year after May 23, 2017; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the Company's Severance Benefit Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.